Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Amphastar Pharma (NQ: AMPH ) 40.67 +1.06 (+2.68%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Amphastar Pharma < Previous 1 2 3 4 5 6 7 Next > 7 Biotech Stocks to Buy on the Dip: June 2024 June 24, 2024 With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. Via InvestorPlace Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts June 18, 2024 These 2 small cap healthcare stocks could boom on a new sector breakout, Wall Street analysts see up to double-digit upside in each Via MarketBeat Topics ETFs Economy Exposures Interest Rates Why the growth investor may take a look at NASDAQ:AMPH. June 05, 2024 AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) may be suited for growth investing, we'll explore why in this article. Via Chartmill Amphastar Announces Additional $50 Million Increase to its Share Buyback Program June 04, 2024 Via ACCESSWIRE Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference June 03, 2024 Via ACCESSWIRE Exploring NASDAQ:AMPH's growth characteristics. May 15, 2024 AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) showing high EPS and FCF growth while beating expectations Via Chartmill Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024 May 08, 2024 Via ACCESSWIRE NASDAQ:AMPH, an undervalued stock with good fundamentals. March 12, 2024 AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH): good value for what you're paying. Via Chartmill Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol May 22, 2024 Via ACCESSWIRE Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade May 16, 2024 The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. Via InvestorPlace Topics Intellectual Property Exposures Intellectual Property Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference May 09, 2024 Via ACCESSWIRE AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024 May 08, 2024 AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca May 01, 2024 The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic... Via Benzinga Topics Intellectual Property Exposures Intellectual Property Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023 February 28, 2024 Via ACCESSWIRE Delving into NASDAQ:AMPH's Growth Prospects. February 28, 2024 Should you consider AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) for growth investing? Via Chartmill Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024 April 30, 2024 Via ACCESSWIRE Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies April 10, 2024 Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential amid a growing market for glucagon products. With promising sales projections... Via Benzinga Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference April 01, 2024 Via ACCESSWIRE Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference March 06, 2024 Via ACCESSWIRE Earnings Outlook For Amphastar Pharma February 27, 2024 Via Benzinga Is NASDAQ:AMPH a Fit for Growth Investing Strategies? February 14, 2024 Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing? Via Chartmill Is NASDAQ:AMPH a Fit for Growth Investing Strategies? February 07, 2024 Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock. Via Chartmill Unlocking the Growth Potential of NASDAQ:AMPH. January 23, 2024 Exploring AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH)'s growth characteristics. Via Chartmill Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024 February 20, 2024 Via ACCESSWIRE CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+ February 13, 2024 CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. Via Investor's Business Daily 3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential February 05, 2024 As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to. Via InvestorPlace Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating January 23, 2024 Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. Via Investor's Business Daily Despite its impressive fundamentals, NASDAQ:AMPH remains undervalued. January 23, 2024 For those who appreciate value investing, AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is a compelling option with its solid fundamentals. Via Chartmill What Vitamins Did For Healthy Living, Stemtech Corporation (OTCQB: STEK) Says It Is Doing For Anti-Aging With Stem Cell Nutrition January 19, 2024 Vitamins may not be a miracle cure, but combined with exercise and a healthy diet, they have the potential to greatly improve health and wellness. It’s no wonder vitamin supplements are a multi-billion... Via Benzinga Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive' January 17, 2024 On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here. Via Benzinga < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.